ArticlePloS one2011
A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Dual-recognizing antibodies targeting CEACAMs in the tumor microenvironment: towards more precise targeting.Cell communication and signaling : CCS · 2026Review
- ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 Blockade.Cancer immunology research · 2025Article
- Proteomic profiling of tumour tissue-derived extracellular vesicles in colon cancer.Journal of extracellular biology · 2024Article
- Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates.Frontiers in oncology · 2023Article
- Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas.Cancers · 2022Review
- CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success?Frontiers of medicine · 2022Review
- Novel Protein-Based Vaccine against Self-Antigen Reduces the Formation of Sporadic Colon Adenomas in Mice.Cancers · 2021Article
- Unifying heterogeneous expression data to predict targets for CAR-T cell therapy.Oncoimmunology · 2021Article
- CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration.The Journal of international medical research · 2020Article
- The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway.Cancer biotherapy & radiopharmaceuticals · 2020Article
- Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer.Frontiers in oncology · 2020Article
- "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer.The Journal of pharmacology and experimental therapeutics · 2018Article
- Prognostic Value of MUC2 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.Gastroenterology research and practice · 2018Review
- Mucin 2 silencing promotes colon cancer metastasis through interleukin-6 signaling.Scientific reports · 2017Article
- The Roles of Carcinoembryonic Antigen in Liver Metastasis and Therapeutic Approaches.Gastroenterology research and practice · 2017Review
- Expression System Based on an MTIIa Promoter to Produce hPSA in Mammalian Cell Cultures.Frontiers in microbiology · 2016Article
- Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells.BMC cancer · 2015Article
- Identification of CEACAM5 as a Biomarker for Prewarning and Prognosis in Gastric Cancer.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2015Article
- A549 cells adapted to high nitric oxide show reduced surface CEACAM expression and altered adhesion and migration properties.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Hidden among the crowd: differential DNA methylation-expression correlations in cancer occur at important oncogenic pathways.Frontiers in genetics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinoembryonic antigen (CEA, CEACAM5, and CD66e) has been found to be associated with various types of cancers, particularly colorectal carcinoma, and developed to be a molecular target for cancer diagnosis and therapy. In present study, we generated a novel anti-CEACAM5 monoclonal antibody, namely mAb CC4, by immunizing mice with living colorectal cancer LS174T cells. Immunohistochemical studies found that mAb CC4 specifically and strongly binds to tumor tissues, especially colorectal adenocarcinoma. In xenografted mice, mAb CC4 is specifically accumulated in tumor site and remarkably represses colorectal tumor growth. In vitro functional analysis showed that mAb CC4 significantly suppresses cell proliferation, migration and aggregation of colorectal cancer cells and also raises strong ADCC reaction. More interestingly, mAb CC4 is able to enhance NK cytotoxicity against MHC-I-deficient colorectal cancer cells by blocking intercellular interaction between epithelial CEACAM5 and NK inhibitory receptor CEACAM1. These data suggest that mAb CC4 has the potential to be developed as a novel tumor-targeting carrier and cancer therapeutic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.